Interview with Tim Hague, the new CEO of Omixon

28/08/2013

Tim Hague, the new CEO of Omixon, answered some of our questions about the future of next generation sequencing and more. What have you been working on at Omixon so far? Up to now, I’ve been Omixon’s Chief Technology Officer, so I’ve been concentrating on leading the research and...

Looking for Your Feedback in Social Media!

20/08/2013

We have been publishing news, analyses and commentaries about next generation sequencing and HLA typing every single day on Facebook, LinkedIn and Twitter as we see amazing potential in using social media channels for spreading the word about these topics and bioinformatics in general. We hope to get feedback from you on any...

Omixon Academy: Collection of Recent Editions

05/08/2013

After weeks of hard work, it’s worth stopping for a moment and checking all the editions that have been published as a part of Omixon Academy. We might call it the first mid-semester. Please see all the entries below in the three categories we have been using. Bioinformatics for...

Introducing the Omixon Academy!

23/07/2013

It’s a great pleasure to present you the Omixon Academy, a series of detailed blog entries and tutorials about bioinformatics and next-generation sequencing. We have been creating such guides for weeks and have received amazing feedback about that. Check it out yourself!

Illumina Applies CE Mark to MiSeqDx™ Cystic Fibrosis System: Omixon Target is Featured!

09/07/2013

We have amazing news today as the first CE mark for next generation sequencing-based molecular diagnostics was just announced. Illumina applied CE mark to MiSeqDx™ Cystic Fibrosis System and Omixon Target is used for analyzing CFTR gene in prenatal labs! An excerpt from the announcement relevant to Omixon Target: Cystic...